Investor science event from ASH 2008 San Francisco, 9 December 2008
|
|
- Kathleen Wilkerson
- 6 years ago
- Views:
Transcription
1 Investor science event from ASH 2008 San Francisco, 9 December 2008
2 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Please see for full information on Roche products mentioned. 2
3 Introduction Dr. Karl Mahler, Head of Investor Relations
4 Agenda MabThera/Rituxan(rituximab) in 1st line CLL 1 (CLL-8 phase III trial) Professor Michael Hallek, Department of Internal Medicine, University of Cologne, Germany MabThera/Rituxan(rituximab) in relapsed CLL (REACH phase III trial) Professor Tadeusz Robak, Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland R7159/GA101 in CD20+ malignant disease (GELA phase I trial) Professor Gilles Salles, Department of Haematology, Hospices Civils of Lyon, Head of the Research Unit Pathologie des Cellules Lymphoïdes, University of Lyon, France MabThera/Rituxan: The answer for all CD20+ disease patients Detlef Krawinkel, MabThera Life Cycle Leader, Roche Pharma Questions & Answers Total duration: Up to 1½ hour 1 CLL = Chronic Lymphocytic Leukemia 4
5 MabThera/Rituxan: Largest hematology product Top-15 products commonly used to treat hematological malignancies Global sales 1 MabThera/Rituxan Quarterly global sales Imatinib Bortezomib Doxorubicin Lenalidomide Thalidomide Dexamethasone Topotecan Dasatinib Prednisone Fludarabine Alemtuzumab Melphalan 1 Source: IMS Q4-97 Q3-98 Q2-99 Q1-00 Q4-00 Q3-01 Q2-02 Q1-03 Q4-03 Q3-04 Q2-05 Q1-06 Q4-06 Q3-07 Q2-08 Cyclophosphamide Bendamustine 5
6 MabThera/Rituxan: New uses have powered growth Roche Pharma still realizing the full RoW potential Global sales MabThera/Rituxan CHF million R/R follicular inhl mono (U.S.) R/R follicular inhl mono (EU) Follicular inhl (JP) anhl (JP) anhl in combo w/chop (EU) 1 st line inhl in combo w/cvp (EU) 1 st line anhl in combo w/chop or other anthracycline-based chemo (U.S.); 1 st line follicular inhl in combo w/cvp (U.S.); maintenance in follicular inhl (U.S.,EU); and rheumatoid arthritis anti-tnf IR in combo w/mtx (U.S., EU) US Japan RoW M M 2008 R/R = Relapsed/Refractory; inhl = indolent Non-Hodgkins Lymphoma (low grade); anhl = aggressive Non-Hodgkins Lymphoma (diffuse large B-cell lymphoma); CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; CVP = cyclophosphamide, vincristine, prednisone; anti-tnf IR = anti-tumor Necrosis Factor Inadequate Responders; MTX = methotrexate 6
7 CLL is the second-largest leukemia worldwide Incidence numbers expected to remain fairly stable Incidence of hematological malignancies Incidence of leukemia subtypes 160, , , ,000 80,000 60,000 40, ,082 8,553 10,879 12,945 9,099 11,516 26,165 27,981 Other ALL CML AML CLL 20,000 0 NHL Leukemia MDS MM HL 23,789 25, ALL = Acute Lymphocytic Leukemia; AML = Acute Myeloid Leukemia; CLL = Chronic Lymphocytic Leukemia; CML = Chronic Myeloid Leukemia Source: Datamonitor, hematological malignancies 03/2007, 12/2007; seven major markets: U.S., France, Germany, Itlay, Spain, UK, Japan 7
8 R7159/GA101: Potential for increased benefits 3rd gen. anti-cd20 molecule with distinct properties Roche's anti-cd20 antibody strategy: Designing specific molecules for specific markets R1594(ocrelizumab) 2nd gen. molecule for use in inflammation, including RA and RRMS R7159/GA101 3rd gen. molecule intended for exclusive use in hematology, including NHL and CLL Strategy intended to eventually replace MabThera/Rituxan before patent expiry during the next decade R7159/GA101 is a fully humanized and glycoengineered type II anti-cd20 monoclonal antibody Genetic engineering of CHO cell line to produce antibody glycosylation and other modifications enabling tailored antibody properties, including Enhanced induction of direct cell death Increased affinity and ADCC 1 Clinical data for MabThera/Rituxan(rituximab) and Herceptin(trastuzumab) support the hypothesis that enhancing the ADCC of the antibody may lead to higher efficacy in cancer treatment Lower CDC 2 activity Currently undergoing phase I/II trials in CD20+ hematological malignancies 1 ADCC = Antibody-Dependent Cell-mediated Cytotoxicity 2 CDC = Complement-Dependent Cytotoxicity 8
9 MabThera/Rituxan(rituximab) in 1st line CLL (CLL-8 phase III trial) Professor Michael Hallek, Department of Internal Medicine, University of Cologne, Germany
10 Rationale I: Fludarabine (F) + cyclophosphamide (C) is superior to F in Previously Untreated CLL Regimen Chl F FC F FC F FC N Med age Rai Stage III- IV, Binet C (%) Grade 3 / 4 ANC (%) % CR % OR Med PFS (mo) Catovsky D, et al. Lancet. 2007;370: ; Flinn FW, et al. J Clin Oncol. 2007;25: ; Eichhorst BF, et al. Blood. 2006;107:
11 Rationale II: improved efficacy by combining FC chemotherapy with rituximab (MD Anderson, historical comparison) Outcome n 6-year OS F % F±M/C R-FC % 77% p value p=0.37 p<0.001 Probability Time (months) Tam CS, et al. Blood 2008;112:
12 CLL8 Study Design Patients with untreated, active CLL and good physical fitness (CIRS 6, creatinine clearance 70 ml/min) R FCR FC 6 courses C1 C2 C3 C4 C5 C6 Follow up Primary endpoint -Progression-free survival (PFS) Secondary endpoints - Overall survival - Rates of molecular, complete and partial remission - Rates of treatment-related adverse effects 12
13 Patients: ITT population (n=817) of the CLL8 protocol FC (n = 409) FCR (n = 408) Female 105 (26%) 105 (26%) Male 304 (74%) 303 (74%) Median age 61 (range 36-81) 61 (range 30-80) Binet A 22 (5.4%) 18 (4.4%) Binet B 259 (63.6%) 263 (64.6%) Binet C 126 (31%) 126 (31%) B symptoms* 197 (48%) 167 (41%) Median cumulative illness rating scale (CIRS) 1 (range 0-8) 1 (range 0-7) Trisomy % 9.6% Del(13q) 59.9% 53.7% Del(11q23) 22.5% 26.7% Del(17p13) 9.5% 7.0% *P<0,05 13
14 Therapy number of courses applied FC FCR
15 All adverse events of CTC grade 3 and 4 Total number of patients with 1 grade 3/4 event FC FCR p 248 (62.6%) 309 (77.5%) < Hematological toxicity 39.4% 55.7 % < Neutropenia 21.0% 33.7% < Leukocytopenia 12.1% 24.0% < Thrombocytopenia 10.9% 7.4% 0.09 Anemia 6.8% 5.4% 0.42 Infection 14.9% 18.8% 0.14 Tumor lysis syndrome 0.5% 0.2% 0.55 Cytokine release syndrome 0.0%
16 Infectious adverse events, grade 3 and 4 FC FCR p Infections, total 14.9% 18.8% 0.14 Infections, if specified 9.3% 13.6% 0.06 Bacterial 1.3% 2.2% 0.30 Viral 4.0% 4.2% 0.90 Fungal 0.3% 0.7% 0.33 Parasitic 0.0% 0.2% 0.32 Differences not statistically significant Treatment related mortality: 2.0% in the FCR and 1.5% in the FC arm 16
17 Response to treatment FC FCR p CR 22.9% 44.5% <0. 01 CR u 5.1% 3.3% 0.22 CR i 1.9% 2.6% 0.52 npr 4.9% 2.8% 0.15 PR 50.4% 39.6% <0.01 SD 6.7% 3.9% 0.08 PD 8.1% 3.3% <
18 Progression free survival: FCR versus FC Median observation time 25.5 months p= Median PFS: 32.3 months for FC vs 42.8 months for FCR 18
19 Progression free survival according to Binet stages Binet Binet A stages A+B Binet stage C p< p=0.44 ORR 93,3% ORR 88,0% 19
20 Overall survival p=0.18 Median observation time 25.5 months 20
21 Overall survival and type of response 21
22 Conclusion: FCR first-line treatment in CLL FCR is superior to FC with regard to: Response rates (CR, OR). Progression-free survival. FCR treatment is safe: FCR causes more neutropenias FCR does not cause more infections or other severe side. FCR is well tolerated in physically fit patients > 65 or 70 years. FCR is the new standard treatment for physically fit CLL patients Data on prognostic factors and minimal residual disease assessment will be presented by Stephan Stilgenbauer (ASH # 781) and 22 Sebastian Böttcher (ASH # 326).
23 MabThera/Rituxan(rituximab) in relapsed CLL (REACH phase III trial) Professor Tadeusz Robak, Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
24 REACH: Study Design R-FC vs FC Relapsed / refractory CLL One previous therapy Binet A, B, C ECOG PS 0 1 FC or prior antibody therapy not allowed R A N D O M I Z E R-FC q4wk 3 FC q4wk 3 R E S T A G E R-FC q4wk 3 CR, PR, (SD) FC q4wk 3 n = sites PD off study Rituximab Fludarabine Cyclophosphamide Cycle mg/m 2 day 0 Cycles mg/m 2 day 1 25 mg/m 2 iv, day mg/m 2 iv, day 1 3 Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
25 REACH: Recruitment by Country (n=552) Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
26 REACH: Demographics and Patient Characteristics FC n = 276 R-FC n = 276 Median age (range) 62 (35 81) 63 (35 83) Female sex 34% 32% A 11% 9% Binet stage B 58% 60% C 31% 31% ECOG PS 0 59% 61% ECOG PS 1 41% 39% B symptoms 31% 26% Median creatinine clearance (ml/min) β2 microglobulin > ULN 78% 76% % are based on patients with information available for the corresponding parameter Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
27 REACH: Selected Stratification Factors FC n = 276 R-FC n = 276 Median time from first diagnosis 3.7 yrs 3.8 yrs Previous therapy Alkylator Refractory 26% 27% Sensitive 56% 55% Purine analog 17% 16% Alkylator fludarabine 1% 2% Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
28 REACH: Treatment Cycles Received %100% 95.6% 92.3% 86.8% 91.2% 76.8% 83.2% 77.4% 72.4% FC (n=272) R-FC (n=274) Patients (n) % 67.5% Cumulative No. of Cycles Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
29 REACH: Selected Grade 3/4 CTC Adverse Events Event type FC (%) n = 272 R-FC (%) n = 274 All Infusion-related (d1-2 of 1 st cycle) 4 6 Tumor Lysis Syndrome 3 2 Neutropenia Febrile Neutropenia Thrombopenia 9 11 AIHA 12 5 Infections Hepatitis B 2 Benign or Malignant Neoplasms 3 7 Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
30 REACH: Response Rates FC (%) n = 276 R-FC (%) n = 276 p CR PR/nPR ORR SD n.d. PD n.d. not evaluable* n.d. *Mainly patients with response that was not confirmed through a second assessment n.d.: not done Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
31 REACH: Primary Endpoint PFS ITT 1.0 Median follow-up 25.3 months Event-free rate 0.4 R-FC Median PFS: 30.6 months No. at risk FC R-FC p = (log-rank) HR 0.65 [0.51; 0.82] FC Median PFS: 20.6 months Months Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
32 REACH: PFS by Previous Treatment (R-FC) ITT 1.0 Median follow-up 25.3 months Event-free rate 0.4 Previous chemotherapy Alkylator refractory Alkylator sensitive Fludarabine No. at risk Alkylator refractory Alkylator sensitive Fludarabine Months Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
33 REACH Binet Subgroups PFS ITT Binet stage HR [95% CI] for PFS A (n = 55) B (n = 326) C (n = 171) 0.75 [0.33; 1.72] 0.65 [0.47; 0.88] 0.61 [0.41; 0.90] Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
34 REACH: PFS by ZAP-70, IgV H ITT ZAP-70 positive (n=173) ZAP-70 negative (n=237) Event-free rate Log-rank test p= Randomised treatment FC R-FC Event-free rate Log-rank test p= Randomised treatment FC R-FC Months Months IgV H unmutated (n=328) IgV H mutated (n=192) Event-free rate Log-rank test p= Randomised treatment FC R-FC Event-free rate Log-rank test p= Randomised treatment FC R-FC Months Months Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
35 REACH: PFS by Cytogenetics ITT del11q (n=115) Trisomy 12 (n=69) 1.0 Randomised treatment 1.0 Randomised treatment Event-free rate Log-rank test p= FC R-FC Months Event-free rate Log-rank test p= FC R-FC Months del17p (n=42) del13q (n=309) Event-free rate Log-rank test p= Randomised treatment FC R-FC Months Event-free rate Log-rank test p= Months Randomised treatment FC R-FC Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
36 REACH: Overall Survival ITT 1.0 Median follow-up 25.3 months 0.8 R-FC Median OS: not reached 0.6 Event-free rate 0.4 No. at risk FC R-FC p = (log rank) HR 0.83 [0.59;1.17] FC Median OS: 51.9 months Months Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
37 REACH Subsequent Therapy FC 69 patients relapsed and received therapy 49% received rituximab-containing regimens R-FC 47 patients relapsed and received therapy 30% received rituximab-containing regimens Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
38 REACH: Summary Rituximab plus FC is significantly superior to FC alone in relapsed / refractory CLL patients Results were robust and consistent in subgroups and across secondary endpoints, including adverse prognostic groups - Binet C -11q -unmutated IgVH, ZAP-70 positive R-FC showed a favorable risk-benefit profile with no new or unexpected safety findings Abstract LBA-1, presented at the 50 th Annual Meeting of the American Society of Hematology, San Francisco, Dec 6 9 th, 2008
39 R7159/GA101 in CD20+ malignant disease (GELA phase I trial) Professor Gilles Salles, Department of Haematology, Hospices Civils of Lyon, Head of the Research Unit Pathologie des Cellules Lymphoïdes, University of Lyon, France
40 GA101: a new anti-cd20 antibody First glycoengineered, humanized, type II CD20 antibody in clinical development Compared with rituximab, GA101 provides: Enhanced direct cell death induction 1,2 Enhanced ADCC 1,2 1. Umaña P, et al. Ann Oncol 2008; 19:Suppl 4;Abstract Umaña P, et al. Blood 2006; 108:(11 Pt 2);Abstract 229.
41 GA101: mechanisms of action Versus type I antibodies Increased direct cell death Unique type II epitope & elbow-hinge modification Increased ADCC via increased affinity to the 'ADCC receptor' FcgRIIIA Effector cell B cell CD20 Lower CDC activity Due to recognition of type II epitope FcgRIIIa Complement
42 BO20999: Trial rationale and design Monoclonal antibody therapy has markedly improved the outcome of B-cell malignancies: but there is still a need for further progress GA101 is a new anti-cd20: Modified type II, glycoengineered and humanized Preclinical data indicate superiority for ADCC and cell death BO20999 is an open-label, multicenter, phase I/II study to explore GA101 activity phase I part to investigate the safety and tolerability of GA101 given as single agent in patients with CD20+ malignant disease non-randomized and adaptive dose-escalating design
43 Study BO20999: Phase I dose-escalation (3+3 design) GA101 single agent (total 9 doses) TUMOR ASSESSMENT weeks CD20+ malignant disease for whom no therapy of higher priority was available n = 3 per cohort Successive cohorts initiated if no DLT Started in September 2007 at 7 sites in France Cohort group GA101 dose Dose 1 / doses / 100 mg 100 / 200 mg 200 / 400 mg 400 / 800 mg 800 / 1200 mg 1200 / 2000 mg 1600 / 1600 / 800 mg GA101 administered as per rituximab administration guidelines
44 GA101 Phase I: Patient characteristics Patients, n 21 Follicular lymphoma 15 Mantle cell lymphoma 3 Diffuse large B-cell lymphoma 1 Lymphocytic/lymphoplasmacytoid lymphoma 1 Waldenström s macroglobulinaemia 1 Male / Female 9 / 12 Haematological parameters Haemoglobin, median (range) 12.9 g/dl ( ) White blood count, median (range) 5.9 x 10 9 /l (3.3 80) Platelets, median (range) 191 x 10 9 /l (89 363) Prior therapies, median (range) 3 (1 7) Prior rituximab 95% Prior ASCT 52% Duration of response to last treatment, median (range) 12 mo (3 112)
45 GA101 well tolerated with preliminary safety profile very similar to rituximab Majority of toxicities grade 1 2 No grade 4 toxicities Four SAEs were observed, one related to the drug that was completely reversible (tumor lysis with thrombocytopenia and neutropenia) Infusion related reactions, mostly grade 1 & 2, more frequent around time of first infusion, less frequent with subsequent infusions: Hypotension Nausea Pyrexia Vomiting Chills Hyperthermia Arthralgia Diarrhoea
46 Analysis of overall response rate in NHL patients 21 patients NHL sub-types 15 FL 1 lymphocytic lymphoma 1 WM 1 DLBCL 3 MCL Best response (%) 4 CR, 5 PR (43%) 8 of 9 responses still ongoing ORR = 47% when only indolent lymphoma (n=17) are considered
47 GA101: Best Tumor Response (18 patients) 150 > 100% % change in indicator lesions a b Patients 150 a = PET-verified CR; b = Death; 1600 / 1600 / 800 mg cohort not included
48 Patient Story: Mantle Cell Lymphoma Patient Male Age 73 Diagnosis: Mantle Cell Lymphoma [Ann Arbor Stage IV/2003] 2 previous lines of therapy R-CHOP [PR] and FC [CR] Baseline WBC: 94x10 9 /l Lymphocyte Count: 92 x 10 9 /l Platelets: 73 x 10 9 /l Splenomegaly (25 cm below costal margin), bulky disease Cycle 1 Day 1 (1200mg): Infusion well tolerated ~ 5 hours post-infusion: Tumor lysis, thrombocytopenia (G4), neutropenia(g3) SAE WBC: 4x10 9 /l 48
49 Patient Story: Mantle Cell Lymphoma Patient Cycle 1 Day 7 WBC: 50x10 9 /l (patient in leukemic phase/re-bound of disease observed) Cycle 1 Day 8 (2000mg) - WBC: 4x10 9 /l and patient feeling very well Cycle 3 Day 1/Patient s disease under control WBC: 2.2x10 9 /l lymphocytes 0.48x10 9 /l platelets 110 x 10 9 /l (spontaneous recovery of platelets) (Spleen 6cm below costal margin and patient feeling very well) Patient received all 9 infusions - Spleen now normal size, WBC and platelets remain normalized - Best response to GA101 = PR GA101 effective as single agent in treatment of MCL patient Patient s quality of live dramatically improved 49
50 Conclusions Safety profile: GA101 is well tolerated with no dose-limiting toxicities very similar to that of rituximab Preliminary PK data suggest that baseline tumor burden is an important co-variate Encouraging efficacy observed in relapsed/ refractory NHL patients: B-CLL data pending (12 patients) Phase II study enrolling indolent and aggressive NHL
51 MabThera/Rituxan: The answer for all CD20+ disease patients Detlef Krawinkel, MabThera Life Cycle Leader, Roche Pharma
52 MabThera/Rituxan: Current status & strategy The new standard of care in CLL Further maintenance indications, ITP, and lifecycle strategy 52
53 MabThera/Rituxan: The success continues Group sales (CHF bn) US Japan RoW Outstanding clinical data and extensive development program Overall survival benefit combined with excellent tolerability Large randomized clinical trials support further registrations: CLL 1 st line CLL relapsed inhl 1 st line maintenance Others Over 1.5 million patients treated
54 Widely utilized in NHL 1 st /2 nd line while CLL and maintenance indications are future growth drivers Depth in core CD-20+ indications inhl 1 st line maintenance Growth drivers, shorter term Growth drivers, longer term Already-launched NHL indications anhl & CLL maintenance CLL Others Breadth in hematology 54
55 Penetration rates validate the opportunities in CLL and further maintenance indications Split of global sales Penetration rates Q Japan 3% Key 5 EU inhl 1st line maintenance 17 % RoW 45% CLL 1 st line 26 % inhl relapsed maintenance 33 % CLL relapsed 38 % US 52% anhl relapsed 64 % inhl relapsed 67 % 2007 CHF 5.5 bn inhl 1 st line 72 % anhl 1 st line 84 % Source: Roche market research Q Note: CLL and maintenance therapy in 1 st line indolent NHL are non-approved indications in EU/RoW 55
56 MabThera/Rituxan Four drivers for continued sales growth in oncology 1. CLL 1 st line and relapsed 2. Expand and prolong treatment (maintenance) 3. Introduce MabThera/Rituxan s.c. as new SoC in maintenance 4. Increase penetration and dosage s.c. = sub-cutaneous; SoC = Standard of Care 56
57 MabThera/Rituxan: Current status & strategy The new standard of care in CLL Further maintenance indications, ITP, and lifecycle strategy 57
58 CLL completes the picture and makes MabThera/Rituxan the answer for all CD20+ patients Typical patient split & EU indications inhl 1 st line 22% 15% inhl relapsed Approval expected 2009 CLL relapsed CLL 1 st line 9% 10% 29% anhl 1 st line 15% anhl relapsed 58
59 Large extension of life free from disease progression CLL 1st line and relapsed/refractory patients CLL8 1 1st line patients REACH 2 relapsed patients 1.0 Randomised treatment FC FCR 1.0 Randomised treatment FC FCR Event HR 0.56 p= FC-R: Median 40 months FC: Median 32 months Progression-free rate HR 0.65 p = FC: Median 20.6 months FC-R: Median 30.6 months ,001 1,092 1,183 1,274 1,365 1,456 Days Time (years) MabThera/Rituxan-chemo vs chemo alone significantly improved PFS in both CLL 1 st line and relapsed/refractory FC = fludarabine, cyclophosphamide; FC-R = fludarabine, cyclophosphamide + MabThera/Rituxan 1 ASH 2008 Abstract 325. Hallek et al. 2 ASH 2008 Abstract (late breaker). Robak et al. 59
60 MabThera/Rituxan: New standard of care in CLL Treatable CLL patients per year (top 5 EU) ~17,000 (which compares to ~50% of the number of treatable patients with inhl) 1st line treatment choice Future MabThera/Rituxan + chemotherapy ~8,500 patients Current Immuno or immunochemotherapy 30% of patients Chemotherapy 70% of patients Relapsed treatment choice Future MabThera/Rituxan + chemotherapy ~8,500 patients Current Immuno or immuno-chemotherapy 50% of patients Chemotherapy 50% of patients Source: Patient case market research Q2 2008; values are rounded 60
61 MabThera/Rituxan: Current status & strategy The new standard of care in CLL Further maintenance indications, ITP, and lifecycle strategy 61
62 MabThera/Rituxan is expected to become standard of care in further indications Ongoing phase III trials inhl 1st line maintenance Trial, study group, PE, time Treatment Patients (EU) PRIMA GELA, France PFS 2011 R-CHOP/CVP-> 2 yrs R maintenance vs. R- CHOP/CVP -> observation 11,500 Rituxan anhl 1st line maintenance NHL 13 trial AGMT, Austria EFS 2012 R-chemo -> 2 yrs R maintenance vs. observation 24,000 CLL maintenance GOELAMS and FCGCLL/WM -, France PFS 2012 R-FC -> 2 yrs R maintenance vs. observation 15,000 Rituxan + Avastin anhl 1st line induction MAIN, Roche-sponsored PFS 2012 R-CHOP vs. Avastin-R- CHOP induction 25,400 62
63 Maintenance treatment in CD20+ hematological malignancies: A very large untapped potential Typical patient split & EU indications Potential approval 2012 CLL 17% anhl 39% 16% inhl relapsed, the only approved EU indication Potential approval % inhl 1 st line 63
64 S.c. formulation will be developed to fully explore the potential in maintenance treatment Formulation will have all the current benefits of MabThera/Rituxan Additional benefits for patients, payers and prescribers Possibility of non-hospital/self administration Improved patient convenience and preference greater independence Less resource-intensive than i.v. administration Reduced medical resource utilization (address capacity issues) Maximizing the overall Roche hematology franchise value 64
65 MabThera/Rituxan: Potential in non-oncological hematology - example First to report randomized data for MabThera/Rituxan-treated ITP 1 patients Treatable patients in EU are around 13,000 Dexamethasone MabThera/Rituxan + dexamethasone p-value n ITT platelet count (%) 50 x 10 9 /l PP platelet count (%) 50 x 10 9 /l ITP = Idiopathic Thrombocytopenic Purpura; ITT = Intent-To-Treat population; PP = Per Protocol population Abstract 1. Session: Lymphoma: Chemotherapy and Clinical Trials Poster II Zaja et al. Sun 7 Dec 2:00 PM. Moscone Center, Halls B & C 65
66 Roche in hematology: More opportunities Phase I Phase II Phase III Registration R7112 R7159 GEN GEN oncology NHL anti-cd20 3rd gen. hem. malig. ABT-263 solid tumors & hem. malig. GEN GEN GEN CD40 Ab diff. large B Cell lymph. Apomab - cancer Apo2L/TRAIL - cancer R105 R105 R105 MabThera CLL relapsed MabThera inhl maint. 1 st line MabThera + Avastin NHL aggr. R105 MabThera CLL 1 st line GEN CD40 Ab NHL/MM/rel.large B-CL NME Additional Indications DBA Oncology R-No. GEN Roche managed Genentech managed Status as of 30 September
67 Questions & Answers Moderator: Dr. Karl Mahler, Head of Investor Relations
68 We Innovate Healthcare 68
Update: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationUBS European Conference 2013
UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationInvestor science conference call ASH 2009 New Orleans, 8 December 2009
Investor science conference call ASH 2009 New Orleans, 8 December 2009 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationMedia Release. Basel, 7 November 2013
Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan
More informationMedia Release. Basel, 5 December 2016
Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationCHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma
Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationMedia Release. Basel, 10 December 2017
Media Release Basel, 10 December 2017 Phase II data showed Roche s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationMedia Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017
Media Release Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationInvestor Update. Downloads. Services PDF. Basel, 23 June 2017
Investor Update Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,
More informationMedia Release. CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationRoche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Media Release Basel, 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationRoche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment
Media Release Basel, 25 July 2017 Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment Approval is based on phase III
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationFocus and value creation
Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationFDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Media Release Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationGENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS
NEWS RELEASE Genentech Contacts: Media / Advocacy: Megan Pace (650) 467-7334 Investor: Susan Morris (650) 225-6523 Karl Mahler 011 41 61 68785 03 Biogen Idec Contacts: Media: Amy Reilly (617) 914-6524
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationMedia Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017
ICML 2017 - BETALUTIN LYMRIT 37-01 STUDY UPDATE JUNE 14 TH, 2017 Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationNEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationRoche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting
Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationLEUKEMIA ANCO s ASH Highlights TOPICS
LEUKEMIA ANCO s ASH Highlights Bruno Medeiros, MD 02/10/2009 TOPICS CML Abstract 181 and 182 Abstract 186 and 335 CLL Abstract 325 and 45 APL Abstract 138 ALL Abstract 427 and 428 1 CML Rosti et al. High
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More information